Data / Drug companies / Monoamine Oxidase Type B Inhibitor
Monoamine Oxidase Type B Inhibitor drugs: 3 drugs from 14 companies in the FDA NDC directory
Monoamine Oxidase Type B Inhibitor is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 19 products in this class from 14 companies, covering 3 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on March 15, 2024.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 14Companies
- 19Products
- 3Drugs by generic name
Drugs in the Monoamine Oxidase Type B Inhibitor class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Selegiline hydrochloride | 14 | 12 |
| Selegiline | 3 | 1 |
| Safinamide mesylate | 2 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Viatris Specialty LLC | 3 | patch | New drug applications (NDA) | February 27, 2006 |
| Apotex Corp. | 2 | capsule; tablet | Generic drugs (ANDA) | July 15, 1997 |
| Bryant Ranch Prepack | 2 | capsule | Generic drugs (ANDA) | April 1, 2021 |
| MDD US Operations LLC, a Subsidiary of Supernus Pharmaceuticals, Inc. | 2 | tablet, film coated | New drug applications (NDA) | May 8, 2017 |
| A-S Medication Solutions | 1 | tablet | Generic drugs (ANDA) | July 6, 1997 |
| A2A Integrated Pharmaceuticals | 1 | tablet | Generic drugs (ANDA) | March 15, 2024 |
| Ani Pharmaceuticals, Inc. | 1 | capsule | Generic drugs (ANDA) | April 1, 2021 |
| Bausch Health US LLC | 1 | tablet, orally disintegrating | New drug applications (NDA) | June 14, 2006 |
| Chartwell RX, LLC | 1 | tablet | Generic drugs (ANDA) | August 2, 1996 |
| Golden State Medical Supply, Inc. | 1 | tablet | Generic drugs (ANDA) | June 6, 1997 |
| I3 Pharmaceuticals, LLC | 1 | tablet | Generic drugs (ANDA) | December 15, 2021 |
| Marlex Pharmaceuticals, Inc. | 1 | capsule | Generic drugs (ANDA) | May 1, 2021 |
| Proficient Rx LP | 1 | capsule | Generic drugs (ANDA) | April 2, 2019 |
| Rising Pharma Holdings, Inc. | 1 | capsule | Generic drugs (ANDA) | April 2, 2019 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 7 | 36.8% |
| Tablet | 6 | 31.6% |
| Patch | 3 | 15.8% |
| Tablet, film coated | 2 | 10.5% |
| Tablet, orally disintegrating | 1 | 5.3% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.